Corcept Therapeutics (CORT) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Corcept Therapeutics published the results on November 3, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison.

• Lifyorli (relacorilant) was approved by the FDA in March 2026 and launched on April 1, 2026, so there is no year-ago Lifyorli revenue.
• Corcept reports GAAP results only; it publishes no adjusted EPS.

Source: Corcept Therapeutics Q3 2026 results, November 3, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Corcept Therapeutics splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Corcept Therapeutics's Korlym and authorized generic revenue was $249 million in Q3 2026, up 20% from $208 million in Q3 2025, 73% of total revenue.
• Corcept Therapeutics's Lifyorli revenue was $91.4 million in Q3 2026, 27% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

Corcept gives a full-year revenue range only, with no quarterly or earnings outlook. The quote is CEO Joseph K. Belanoff's, from the release.

In its Q3 2026 release, Corcept Therapeutics said:

“We expect continued growth in both businesses and have reiterated our 2026 revenue guidance of $1.1-$1.2 billion.”

Source: Corcept Q3 2026 release, Nov 3, 2026.

This is the company's own guidance as of Nov 3, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the CORT forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP product revenue, net and diluted EPS, each as first reported in that quarter's release.

We do not hold a confirmed date for Corcept Therapeutics's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 3, 2026

Corcept Therapeutics now sells drugs in two businesses. Korlym, introduced in 2012 as the first FDA-approved medication for endogenous Cushing's syndrome, and its authorized generic brought in $249.1 million of Q3 2026 revenue of $340.5 million. Lifyorli (relacorilant), approved in March 2026 with nab-paclitaxel for platinum-resistant ovarian cancer and launched April 1, brought in $91.4 million. Total revenue rose 64% from $207.6 million a year earlier. (Corcept Q3 2026 release, Nov 3, 2026; Corcept Form 10-Q, Q3 2026, Nov 3, 2026)

In the hypercortisolism business, higher sales volume accounted for 75.2 percent of the year-over-year increase. The rest came from a price increase taken in August 2025 and improved payor reimbursement at Corcept's current specialty pharmacy, partly offset by more volume of the lower-priced authorized generic. (Corcept Form 10-Q, Q3 2026, Nov 3, 2026)

Lifyorli revenue grew 92 percent from the second quarter. Corcept said more than 2,300 patients have received it and more than 1,700 physicians have prescribed it since launch. In September 2026 the European Medicines Agency's CHMP recommended approval of relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer, and a separate relacorilant application for Cushing's syndrome has an FDA decision date of December 17, 2026. (Corcept Q3 2026 release, Nov 3, 2026)

Corcept's Cushing's revenue runs through one specialty pharmacy. Curant Health Georgia, the primary vendor since the transition finished in the first quarter of 2026, collects payments from insurers representing more than 99 percent of Corcept's hypercortisolism revenue. The previous vendor, Optime Care, served from 2017 to 2025 and was unable to fully meet demand in 2025. (Corcept Form 10-Q, Q3 2026, Nov 3, 2026)

Corcept Therapeutics reports GAAP results only. Diluted EPS was $1.01 in Q3 2026, against $0.16 a year earlier, on net income of $126.8 million. Operating expenses rose to $225.7 million from $197.4 million: selling, general and administrative expense climbed to $164.4 million from $124.0 million, while research and development fell to $56.7 million from $68.8 million. Cost of sales was $4.6 million. (Corcept Q3 2026 release, Nov 3, 2026)

Corcept recorded a $6.5 million income tax benefit on $120.3 million of pre-tax income, which it attributed mainly to higher stock compensation deductions. Stock-based compensation totaled $29.8 million in the quarter. (Corcept Q3 2026 release, Nov 3, 2026; Corcept Form 10-Q, Q3 2026, Nov 3, 2026)

EPS uses the two-class method because restricted stock awards are participating shares, so the numerator is net income attributable to common stockholders of $124.5 million. Diluted shares were 123.2 million, against 119.4 million. Corcept bought $43.7 million of its common stock in the quarter under its repurchase program. (Corcept Q3 2026 release, Nov 3, 2026; Corcept Form 10-Q, Q3 2026, Nov 3, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Corcept Therapeutics gives one number: full-year revenue. With Q3 results it reiterated 2026 revenue guidance of $1.1 to $1.2 billion, after revenue of $761.5 million in the first nine months. It gives no EPS outlook. (Corcept Q3 2026 release, Nov 3, 2026)

Corcept also listed pipeline dates: EU approval of relacorilant in ovarian cancer expected by the end of 2026, results from BELLA Parts B and C, TRIDENT and SYNERGY by the end of next year, and a Phase 3 ALS study of dazucorilant planned to begin next year. (Corcept Q3 2026 release, Nov 3, 2026)

A consensus figure is the average of the models published by the analysts who cover Corcept Therapeutics, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Corcept Therapeutics's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning CORT is on is CORT a buy or a sell?, what analysts expect next is on the CORT forecast, and what the company does is on the Corcept Therapeutics (CORT) stock page.

Every number on this page can be traced to a document Corcept Therapeutics published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.